SCHEMBL177579

SCHEMBL177579

CS(=O)(=O)Oc1ccc2c(C(F)(F)F)nn(C3CCCCO3)c2c1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGAT2 Q96PD7 1/20 0.33
ALDH1A1 P00352 2/20 0.33
LMNA P02545 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
HPGD P15428 1/20 0.33
KDM4E B2RXH2 1/20 0.32
GAA P10253 1/20 0.32
ATR Q13535 4/20 0.32
CA2 P00918 1/20 0.32
CA5A P35218 1/20 0.32
RXRA P19793 1/20 0.32
RXRB P28702 1/20 0.32
RXRG P48443 1/20 0.32
CYP4F2 P78329 3/20 0.31
CYP4A11 Q02928 3/20 0.31
ENPP3 O14638 1/20 0.31
ENPP1 P22413 1/20 0.31
ALPL P05186 1/20 0.31
ALPI P09923 1/20 0.31
HTR6 P50406 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL176922 0.79 CYP4F2 (0.42) DGAT2GAAATRRXRARXRB
SCHEMBL177354 0.77 CYP11B2 (0.37) DGAT2ALDH1A1SMN1; SMN2ATRRXRA
SCHEMBL14800689 0.75 RXRA (0.37) ALDH1A1LMNAHPGDKDM4EATR
SCHEMBL22890826 0.73 RXRA (0.37) ALDH1A1LMNAKDM4EGAAATR
SCHEMBL14800443 0.73 CYP4F2 (0.42) DGAT2GAAATRRXRARXRB
SCHEMBL18281890 0.71 RORC (0.36) DGAT2ATRRXRARXRBRXRG
SCHEMBL18369828 0.70 RXRA (0.41) ALDH1A1LMNAATRRXRARXRB
SCHEMBL18370091 0.70 AR (0.36) ATRRXRARXRBRXRGCYP4F2
SCHEMBL20593144 0.69 CTSC (0.35) ATRRXRARXRBRXRGCYP4F2
SCHEMBL30048911 0.69 RAB9A (0.37) DGAT2ALDH1A1HPGDKDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8008506-B2 Indazole compounds ASAHI KASEI PHARMA CORPORATION (JP) 2011-08-30 US disclosed
US-8008506-B2 Indazole compounds ASAHI KASEI PHARMA CORPORATION (JP) 2011-08-30 US disclosed
US-8008506-B2 Indazole compounds ASAHI KASEI PHARMA CORPORATION (JP) 2011-08-30 US disclosed
EP-2345644-A1 INDAZOLE COMPOUND Asahi Kasei Pharma Corporation (JP) 2011-07-20 EP disclosed
US-20100160256-A1 INDAZOLE COMPOUNDS ASAHI KASEI PHARMA CORPORATION (JP) 2010-06-24 US disclosed
US-20100160256-A1 INDAZOLE COMPOUNDS ASAHI KASEI PHARMA CORPORATION (JP) 2010-06-24 US disclosed
US-20100160256-A1 INDAZOLE COMPOUNDS ASAHI KASEI PHARMA CORPORATION (JP) 2010-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160256-A1 INDAZOLE COMPOUNDS GPR119, ADRB1, ADRA1A DGAT2 1821/4885ALDH1A1 131/4885LMNA 4123/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.